"In order to provide necessary flexibility regarding borrowings of the company in an optimal manner depending on the market conditions, the company proposes to offer, issue and allot redeemable NCDs up to Rs 1,000 crore...," Jubilant Life Sciences said in the notice to shareholders that it filed to the BSE.
This approval to the board to raise the amount also stipulates that this could be done in one or more series/ tranches during a period of one year from the date of passing the resolution, it added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
